{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:36:09Z","timestamp":1760204169313},"reference-count":149,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.dld.2006.04.009","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T03:34:33Z","timestamp":1149651273000},"page":"789-801","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives"],"prefix":"10.1016","volume":"38","author":[{"given":"A.","family":"Federico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Trappoliere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loguercio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2006.04.009_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1467-789X.2004.00126.x","article-title":"Hepatic steatosis in obese patients: clinical aspects and prognostic significance","volume":"5","author":"Festi","year":"2004","journal-title":"Obes Rev"},{"key":"10.1016\/j.dld.2006.04.009_bib2","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1053\/j.gastro.2004.09.021","article-title":"Obesity and hepatocellular carcinoma","volume":"127","author":"Caldwell","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clinbiochem.2004.10.014","article-title":"Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management","volume":"38","author":"Portincasa","year":"2005","journal-title":"Clin Biochem"},{"key":"10.1016\/j.dld.2006.04.009_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.dld.2004.07.013","article-title":"The aetiology of chronic hepatitis in Italy: results from a multicentre national study","volume":"36","author":"Stroffolini","year":"2004","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jmv.20313","article-title":"The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases","volume":"75","author":"Sagnelli","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2006.04.009_bib6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00042737-200411000-00002","article-title":"The epidemiology of fatty liver","volume":"16","author":"Bellentani","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jhep.2004.07.010","article-title":"Silent non-alcoholic fatty liver disease: a clinical-histological study","volume":"41","author":"Sorrentino","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib8","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMoa031049","article-title":"Obesity and the metabolic syndrome in children and adolescents","volume":"350","author":"Weiss","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.04.009_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0168-8278(01)00192-1","article-title":"Non-alcoholic fatty liver disease in an area of Southern Italy: main clinical, histological, and pathophysiological aspects","volume":"35","author":"Loguercio","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.dld.2004.01.022","article-title":"Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver","volume":"36","author":"Loguercio","year":"2004","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2036.2005.02596.x","article-title":"Review article: non-alcoholic fatty liver disease and hepatitis C-risk factors and clinical implications","volume":"22","author":"Sanyal","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.20750","article-title":"Steatosis: co-factor in other liver diseases","volume":"42","author":"Powell","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-8278(03)00479-3","article-title":"Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States","volume":"40","author":"Hu","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/jhep.2003.50350","article-title":"High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C","volume":"38","author":"Bressler","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.20207","article-title":"Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index","volume":"39","author":"Sud","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.03.020","article-title":"Insulin resistance and insulin secretion in chronic hepatitis C virus infection","volume":"41","author":"Narita","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-1746.2005.04221.x","article-title":"Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?","volume":"21","author":"Cinar","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2005.09.002","article-title":"Non-alcoholic steatohepatitis: from cell biology to clinical practice","volume":"44","author":"Cortez-Pinto","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.dld.2004.01.012","article-title":"Searching for coeliac disease in patients with non-alcoholic fatty liver disease","volume":"36","author":"Bardella","year":"2004","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1089-3261(05)70116-1","article-title":"Iron-induced liver injury","volume":"4","author":"Bonkovsky","year":"2000","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2036.2003.01689.x","article-title":"Systematic review: hepatotoxic events associated with herbal medicinal products","volume":"18","author":"Pittler","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2036.2004.02092.x","article-title":"Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs","volume":"20","author":"Rubenstein","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib24","first-page":"221","article-title":"The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis","volume":"68","author":"Ataseven","year":"2005","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.dld.2006.04.009_bib25","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.dld.2006.04.009_bib26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0016-5085(03)00395-0","article-title":"Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States","volume":"124","author":"Ruhl","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib27","first-page":"820","article-title":"Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies","volume":"40","author":"Fassio","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2004.04.004","article-title":"The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease","volume":"8","author":"McCullough","year":"2004","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/bega.2002.0325","article-title":"The metabolic abnormalities associated with non-alcoholic fatty liver disease","volume":"16","author":"Haque","year":"2002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib30","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/hep.20219","article-title":"Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption","volume":"39","author":"Laine","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1542-3565(04)00625-1","article-title":"Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease","volume":"3","author":"Naveau","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib32","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jhep.2004.08.020","article-title":"Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease","volume":"41","author":"Angulo","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib34","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/00365520310003877","article-title":"Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis","volume":"38","author":"Comlekci","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib35","first-page":"2804","article-title":"Nonalcoholic fatty liver: does it have to be biopsed?","volume":"1","author":"Rubbia-Brandt","year":"2005","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.dld.2006.04.009_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ncpgasthep0116","article-title":"Treatment strategies in nonalcoholic fatty liver disease","volume":"2","author":"Tilg","year":"2005","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","article-title":"The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies","volume":"42","author":"Adams","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib38","first-page":"98","article-title":"Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss","volume":"26","author":"Luyckx","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.dld.2006.04.009_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bbagen.2003.11.002","article-title":"Food restriction affects energy metabolism in rat liver mitochondria","volume":"1670","author":"Dumas","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dld.2006.04.009_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0531-5565(03)00151-7","article-title":"Mitochondrion-mediated apoptosis is enhanced in long-lived alpha-MUPA transgenic mice and calorically restricted wild-type mice","volume":"38","author":"Tirosh","year":"2003","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.dld.2006.04.009_bib41","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2004.11.022","article-title":"Evaluation and management of non-alcoholic steatohepatitis","volume":"42","author":"Ramesh","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10620-006-3077-3","article-title":"Nonalcoholic fatty liver disease treated by gastroplasty","volume":"51","author":"Jaskiewicz","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.sla.0000179652.07502.3f","article-title":"Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome","volume":"242","author":"Mattar","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2006.04.009_bib44","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1053\/j.gastro.2006.03.041","article-title":"NAFLD, obesity, and bariatric surgery","volume":"130","author":"Angulo","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1381\/0960892055002239","article-title":"Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity","volume":"15","author":"Stratopoulos","year":"2005","journal-title":"Obes Surg"},{"key":"10.1016\/j.dld.2006.04.009_bib46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1572-0241.2006.00419.x","article-title":"Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery","volume":"101","author":"Barker","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss","volume":"39","author":"Dixon","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/jhep.2003.50132","article-title":"Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis","volume":"37","author":"Musso","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib49","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1572-0241.2005.41334.x","article-title":"One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study","volume":"100","author":"Huang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1023\/B:DDAS.0000043367.69470.b7","article-title":"Dietary composition and nonalcoholic fatty liver disease","volume":"49","author":"Solga","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/bega.2002.0332","article-title":"Animal models of steatohepatitis","volume":"16","author":"Koteish","year":"2002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/gut.2003.027581","article-title":"Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life","volume":"53","author":"Hickman","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.dld.2006.04.009_bib53","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diabetes.52.9.2191","article-title":"Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity","volume":"52","author":"Goodpaster","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.dld.2006.04.009_bib54","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.mehy.2003.12.041","article-title":"Aerobic exercise: a potential therapeutic intervention for patients with liver disease","volume":"62","author":"Bergasa","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.dld.2006.04.009_bib55","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.metabol.2004.01.008","article-title":"Central hypothalamic-pituitary-adrenal activity and the metabolic syndrome: studies using the corticotrophin-releasing hormone test","volume":"53","author":"Ward","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.dld.2006.04.009_bib56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib57","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2036.2004.02153.x","article-title":"A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients","volume":"20","author":"Harrison","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib58","first-page":"189","article-title":"The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis","volume":"12","author":"Sabuncu","year":"2003","journal-title":"Rom J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib59","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/BF03347560","article-title":"Glucagon-like peptide 1 (GLP-1) and metabolic diseases","volume":"28","author":"Rotella","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.dld.2006.04.009_bib60","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib61","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1155\/2003\/857869","article-title":"Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis","volume":"17","author":"Kiyici","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0168-8278(02)00441-5","article-title":"Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study","volume":"38","author":"Merat","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib64","doi-asserted-by":"crossref","unstructured":"Ahmed MH. Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers. Med Hypotheses 2005 [Epub ahead of print].","DOI":"10.1016\/j.mehy.2005.09.003"},{"key":"10.1016\/j.dld.2006.04.009_bib65","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3748\/wjg.v11.i12.1737","article-title":"Adiponectin as a protective factor in hepatic steatosis","volume":"11","author":"Mendez-Sanchez","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2265.2004.02151.x","article-title":"Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals","volume":"61","author":"Targher","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.dld.2006.04.009_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease","volume":"152","author":"Pagano","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.dld.2006.04.009_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dld.2006.04.009_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00592-005-0187-x","article-title":"Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity","volume":"42","author":"Hasegawa","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.dld.2006.04.009_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1381\/0960892053923789","article-title":"Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin","volume":"15","author":"Ballantyne","year":"2005","journal-title":"Obes Surg"},{"key":"10.1016\/j.dld.2006.04.009_bib71","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1126\/science.1092341","article-title":"Regulation of fasted blood glucose by resistin","volume":"303","author":"Banerjee","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.dld.2006.04.009_bib72","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.ijo.0802625","article-title":"Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients","volume":"28","author":"Bajaj","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.dld.2006.04.009_bib73","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1172\/JCI200421270","article-title":"Role of resistin in diet-induced hepatic insulin resistance","volume":"114","author":"Muse","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.dld.2006.04.009_bib74","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Kim","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.dld.2006.04.009_bib75","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1440-1746.2004.03312.x","article-title":"Non-alcoholic steatohepatitis in type 2 diabetes mellitus","volume":"19","author":"Gupte","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/00365520410006431","article-title":"High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease","volume":"39","author":"Friis-Liby","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib77","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000073579","article-title":"The insulin resistance syndrome: implications for thrombosis and cardiovascular disease","volume":"32","author":"Juhan-Vague","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.dld.2006.04.009_bib78","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.2337\/diacare.27.10.2498","article-title":"Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation","volume":"27","author":"Targher","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dld.2006.04.009_bib79","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3748\/wjg.v11.i12.1848","article-title":"Hepatic steatosis is associated with an increased risk of carotid atherosclerosis","volume":"11","author":"Volzke","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib80","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dld.2006.04.009_bib81","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/sj.ijo.0802494","article-title":"Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation","volume":"27","author":"Moller","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.dld.2006.04.009_bib82","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1440-1746.2004.03349.x","article-title":"Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease","volume":"19","author":"Yeon","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib83","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2174\/1566524033479537","article-title":"Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis","volume":"3","author":"Yu","year":"2003","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.dld.2006.04.009_bib84","doi-asserted-by":"crossref","first-page":"28918","DOI":"10.1074\/jbc.M910350199","article-title":"Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting","volume":"275","author":"Hashimoto","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dld.2006.04.009_bib85","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2005.11.030","article-title":"Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?","volume":"44","author":"Larter","year":"2006","journal-title":"J. Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib87","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib88","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib89","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2005.02420.x","article-title":"A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis","volume":"21","author":"Schwimmer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dld.2006.04.009_bib91","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib92","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2006.05.005","article-title":"Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement","volume":"4","author":"Lutchman","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib93","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/jhep.2003.50420","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib94","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib95","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.cld.2005.07.002","article-title":"Approach to the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"9","author":"Ong","year":"2005","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1517\/13543784.14.1.29","article-title":"Recent advances in the treatment of non-alcoholic fatty liver disease","volume":"14","author":"Mendes","year":"2005","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.dld.2006.04.009_bib97","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10620-005-1267-z","article-title":"Nonalcoholic fatty liver disease: a clinical review","volume":"50","author":"Sass","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib98","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0168-8278(03)00097-7","article-title":"Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics","volume":"38","author":"Solga","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib99","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hep.20220","article-title":"Gut flora-based therapy in liver disease? The liver cares about the gut","volume":"39","author":"Solga","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib100","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/j.1572-0241.2002.05942.x","article-title":"Gut-liver axis: a new point of attack to treat chronic liver damage?","volume":"97","author":"Loguercio","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib101","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1572-0241.2001.03702.x","article-title":"Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis","volume":"96","author":"Nair","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib102","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1097\/01.mcg.0000128934.53920.1d","article-title":"Probiotics: a potential target for the prevention and treatment of steatohepatitis","volume":"38","author":"Nardone","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib104","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","article-title":"Beneficial effects of a probiotic VSL(3 on parameters of liver dysfunction in chronic liver diseases","volume":"39","author":"Loguercio","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib105","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s10620-005-2720-8","article-title":"Increased orocecal transit time in patients with nonalcoholic fatty liver disease","volume":"50","author":"Soza","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib106","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.3748\/wjg.v11.i32.5053","article-title":"Effect of lactulose on establishment of a rat non-alcoholic steatohepatitismodel","volume":"11","author":"Fan","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib107","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hep.20683","article-title":"Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism","volume":"41","author":"Galli","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib108","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2005.03.004","article-title":"NASH: a mitochondrial disease","volume":"42","author":"Pessayre","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0891-5849(02)01167-X","article-title":"Oxidative stress in viral and alcoholic hepatitis","volume":"34","author":"Loguercio","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.dld.2006.04.009_bib110","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/j.1572-0241.2001.04129.x","article-title":"Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study","volume":"96","author":"Abdelmalek","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib111","first-page":"722","article-title":"Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study","volume":"50","author":"Miglio","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.dld.2006.04.009_bib112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2891-2-9","article-title":"Vitamin C and Vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats","volume":"2","author":"Oliveira","year":"2003","journal-title":"Nutr J"},{"key":"10.1016\/j.dld.2006.04.009_bib113","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2006.04.009_bib114","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1046\/j.1365-2036.2001.01083.x","article-title":"Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study","volume":"15","author":"Hasegawa","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib115","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1067\/mpd.2000.106566","article-title":"Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study","volume":"136","author":"Lavine","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.dld.2006.04.009_bib116","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/0016-5085(92)70034-9","article-title":"Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients","volume":"102","author":"Buchman","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0300-483X(99)00060-8","article-title":"Dietary beta-carotene protects lung and liver parenchyma of rats treated with monocrotaline","volume":"137","author":"Baybutt","year":"1999","journal-title":"Toxicology"},{"key":"10.1016\/j.dld.2006.04.009_bib118","first-page":"670","article-title":"The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet","volume":"26","author":"Nakano","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib119","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(04)00065-0","article-title":"Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation","volume":"40","author":"Hiroko","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.07.006","article-title":"Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements","volume":"206","author":"Shalan","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.dld.2006.04.009_bib121","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0168-8278(98)80285-7","article-title":"Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial","volume":"28","author":"Par\u00e9s","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib122","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0006-2952(85)90421-6","article-title":"Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat","volume":"34","author":"Valenzuela","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dld.2006.04.009_bib123","first-page":"465","article-title":"Silymarin: a review of its clinical properties in the management of hepatic disorders","volume":"15","author":"Wellington","year":"2001","journal-title":"Bio Drugs"},{"key":"10.1016\/j.dld.2006.04.009_bib124","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dld.2005.05.011","article-title":"Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats","volume":"37","author":"Di Sario","year":"2005","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2006.04.009_bib125","first-page":"299","article-title":"The treatment of NAFLD","volume":"9","author":"Trappoliere","year":"2005","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib126","unstructured":"Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non alcoholic fatty liver disease: preliminary observations. Letter to Gut [in press]."},{"key":"10.1016\/j.dld.2006.04.009_bib127","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","article-title":"Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases","volume":"13","author":"Trauner","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2006.04.009_bib128","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib129","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.transproceed.2004.08.061","article-title":"Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats","volume":"36","author":"Kaibori","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2006.04.009_bib130","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0168-8278(02)00245-3","article-title":"Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production","volume":"37","author":"Di Sario","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1152\/ajpgi.00474.2002","article-title":"Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth","volume":"285","author":"Xu","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.dld.2006.04.009_bib132","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/hep.510280612","article-title":"Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats","volume":"28","author":"Fort","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib133","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1248\/bpb.20.417","article-title":"Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction","volume":"20","author":"Park","year":"1997","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dld.2006.04.009_bib134","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0168-8278(96)80147-4","article-title":"Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression","volume":"24","author":"Ma","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib135","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0168-8278(97)80473-4","article-title":"Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation","volume":"26","author":"Oberti","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib136","doi-asserted-by":"crossref","unstructured":"Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005;CD002148.","DOI":"10.1002\/14651858.CD002148.pub2"},{"key":"10.1016\/j.dld.2006.04.009_bib137","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.gastro.2005.01.057","article-title":"Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival","volume":"128","author":"Morgan","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib138","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.lfs.2003.09.059","article-title":"Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell","volume":"74","author":"Sakaida","year":"2004","journal-title":"Life Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib139","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1248\/bpb.25.1417","article-title":"Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine-induced liver injury rats","volume":"25","author":"Kusunose","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dld.2006.04.009_bib140","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1053\/gast.2001.27188","article-title":"Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats","volume":"121","author":"Wright","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2006.04.009_bib141","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hep.20254","article-title":"Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells","volume":"40","author":"Orr","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib142","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1023\/B:DDAS.0000043369.88701.5b","article-title":"Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats","volume":"49","author":"Wei","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.04.009_bib143","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/hep.20369","article-title":"Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats","volume":"40","author":"Guo","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib144","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1005512014280","article-title":"Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin","volume":"32","author":"Masini","year":"2000","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.dld.2006.04.009_bib146","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0168-8278(01)00148-9","article-title":"Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1 and TIMP-1","volume":"35","author":"Jia","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.04.009_bib147","first-page":"193","article-title":"Effects of a new pharmacological complex (silybin+vitamin E+phospholipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non-alcoholic fatty liver disease: a preliminary open pilot study","volume":"51","author":"Trappoliere","year":"2005","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.dld.2006.04.009_bib148","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.04.009_bib149","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865806001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865806001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T02:02:29Z","timestamp":1627437749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865806001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":149,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1590865806001745"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2006.04.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}